Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib.
Lars E KristensenBruce E StroberDenis PoddubnyyYing Ying LeungHyejin JoKenneth KwokIvana VranicDona L FleishakerLara FallonArne YndestadDafna D GladmanPublished in: Therapeutic advances in musculoskeletal disease (2023)
• It is important to measure risk and assess history of CV disease in people with PsA and PsO, including those taking tofacitinib.• We should test for cancer in people with high risk of CV disease.